Since 2014, several PARP inhibitors—including olaparib, rucaparib, niraparib, talazoparib, fluzoparib, and pamiparib—have been approved for clinical use, achieving remarkable outcomes in the treatment of BRCA‐mutant tumours. This evidence concerns the gene PARP1 and neoplasm.